Search alternatives:
significant decrease » significant increase (Expand Search), significantly increased (Expand Search)
greatest decrease » treatment decreased (Expand Search), greater increase (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
significant decrease » significant increase (Expand Search), significantly increased (Expand Search)
greatest decrease » treatment decreased (Expand Search), greater increase (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
-
15821
Table 1_Exploring the liver microenvironment following successful therapy for HCV: gene expression profiling and residual T cell infiltration.docx
Published 2025“…In parallel, spectral imaging further revealed post-treatment shifts in macrophage populations, with a significant decrease in inflammatory subsets (CD14+, CD14+/Mac387+, p<0.05) and an increase in anti-inflammatory subsets (CD16+, CD16+/CD163+, CD16+/CD68+, p<0.05). …”
-
15822
Image 3_Exploring the liver microenvironment following successful therapy for HCV: gene expression profiling and residual T cell infiltration.tif
Published 2025“…In parallel, spectral imaging further revealed post-treatment shifts in macrophage populations, with a significant decrease in inflammatory subsets (CD14+, CD14+/Mac387+, p<0.05) and an increase in anti-inflammatory subsets (CD16+, CD16+/CD163+, CD16+/CD68+, p<0.05). …”
-
15823
Data Sheet 1_Enhancing AAV-microdystrophin gene therapy after repeat dosing by blocking phagocytosis.docx
Published 2025“…</p>Results<p>Viral load was significantly increased by 77-fold in white blood cells after two rAAV9-microdystrophin doses compared to mice receiving a single dose. …”
-
15824
Clinical and biochemical determinants of length of stay, readmission and recurrence in patients admitted with diabetic ketoacidosis
Published 2024“…<p>The increasing prevalence of diabetic ketoacidosis (DKA) related admissions poses a significant burden on the healthcare systems globally. …”
-
15825
Ydj1 acetylation alters interactions with client proteins.
Published 2024“…Interactors are colored according to change in interaction as follows: green (significant increase), red (significant decrease), or purple (no significant change) 6KQ/6KR. …”
-
15826
Signal denoising in modular spiking networks
Published 2024“…These ordered projections arrange and preserve the relative organization of cells between distinct populations and have been the object of many empirical studies. From providing a structural scaffold for spatial information segregation to the organization of spatiotemporal feature maps, these ubiquitous anatomical features are known to have significant, albeit not entirely understood, functional consequences.…”
-
15827
Figure 1 from Tumor-Immune Signatures of Treatment Resistance to Brentuximab Vedotin with Ipilimumab and/or Nivolumab in Hodgkin Lymphoma
Published 2025“…<b>C,</b> Summary heatmap showing the log<sub>2</sub>-fold change (log<sub>2</sub>FC) between time points and treatments. The changes with a positive log<sub>2</sub>FC over time in color blue are associated with a decrease over time and red with an increase over time. …”
-
15828
Live/Dead cells 4 days incubation.
Published 2025“…<div><p>Traditionally, the yeast cell wall (YCW) has limited applications because of its low solubility. To overcome this, a novel method was developed using a hydrothermal reaction to enhance its solubility and decrease its viscosity; this resulted in the production of a soluble form of YCW, known as the YCW treated with hydrothermal reaction (YCW-H), with broader chemical composition. …”
-
15829
CPSF6-NLS chimeras confer virus-specific infectivity defects.
Published 2025“…Relative infectivity in CsA-treated growth arrested cells to untreated WT HIV-1-infected (C) and P90A infected (D) growth arrested cells displays a decrease to no change in infectivity for all CPSF6-NLS cell lines except for CPSF6-NP NLS cells during WT HIV-1 infection, which display an almost twofold increased infection. …”
-
15830
ESR Fig 4, Table 1 data.
Published 2025“…<div><p>Traditionally, the yeast cell wall (YCW) has limited applications because of its low solubility. To overcome this, a novel method was developed using a hydrothermal reaction to enhance its solubility and decrease its viscosity; this resulted in the production of a soluble form of YCW, known as the YCW treated with hydrothermal reaction (YCW-H), with broader chemical composition. …”
-
15831
Table 2_Wip1 inhibitor CCT007093 alleviates immune exhaustion of lymphocytes via p65 NF-κB and YY1 in chronic hepatitis B virus infection in mice.xlsx
Published 2025“…</p>Methods<p>We focused on CCT007093, a Wip1 inhibitor, screened for its distinctive capacity to simultaneously decrease PD-1 and FcγRIIB expression in B cells.…”
-
15832
Image 2_Wip1 inhibitor CCT007093 alleviates immune exhaustion of lymphocytes via p65 NF-κB and YY1 in chronic hepatitis B virus infection in mice.tif
Published 2025“…</p>Methods<p>We focused on CCT007093, a Wip1 inhibitor, screened for its distinctive capacity to simultaneously decrease PD-1 and FcγRIIB expression in B cells.…”
-
15833
Image 7_Wip1 inhibitor CCT007093 alleviates immune exhaustion of lymphocytes via p65 NF-κB and YY1 in chronic hepatitis B virus infection in mice.tif
Published 2025“…</p>Methods<p>We focused on CCT007093, a Wip1 inhibitor, screened for its distinctive capacity to simultaneously decrease PD-1 and FcγRIIB expression in B cells.…”
-
15834
Image 6_Wip1 inhibitor CCT007093 alleviates immune exhaustion of lymphocytes via p65 NF-κB and YY1 in chronic hepatitis B virus infection in mice.tif
Published 2025“…</p>Methods<p>We focused on CCT007093, a Wip1 inhibitor, screened for its distinctive capacity to simultaneously decrease PD-1 and FcγRIIB expression in B cells.…”
-
15835
Table 1_Wip1 inhibitor CCT007093 alleviates immune exhaustion of lymphocytes via p65 NF-κB and YY1 in chronic hepatitis B virus infection in mice.xlsx
Published 2025“…</p>Methods<p>We focused on CCT007093, a Wip1 inhibitor, screened for its distinctive capacity to simultaneously decrease PD-1 and FcγRIIB expression in B cells.…”
-
15836
Image 4_Wip1 inhibitor CCT007093 alleviates immune exhaustion of lymphocytes via p65 NF-κB and YY1 in chronic hepatitis B virus infection in mice.tif
Published 2025“…</p>Methods<p>We focused on CCT007093, a Wip1 inhibitor, screened for its distinctive capacity to simultaneously decrease PD-1 and FcγRIIB expression in B cells.…”
-
15837
Image 1_Wip1 inhibitor CCT007093 alleviates immune exhaustion of lymphocytes via p65 NF-κB and YY1 in chronic hepatitis B virus infection in mice.tif
Published 2025“…</p>Methods<p>We focused on CCT007093, a Wip1 inhibitor, screened for its distinctive capacity to simultaneously decrease PD-1 and FcγRIIB expression in B cells.…”
-
15838
Image 8_Wip1 inhibitor CCT007093 alleviates immune exhaustion of lymphocytes via p65 NF-κB and YY1 in chronic hepatitis B virus infection in mice.tif
Published 2025“…</p>Methods<p>We focused on CCT007093, a Wip1 inhibitor, screened for its distinctive capacity to simultaneously decrease PD-1 and FcγRIIB expression in B cells.…”
-
15839
Image 5_Wip1 inhibitor CCT007093 alleviates immune exhaustion of lymphocytes via p65 NF-κB and YY1 in chronic hepatitis B virus infection in mice.tif
Published 2025“…</p>Methods<p>We focused on CCT007093, a Wip1 inhibitor, screened for its distinctive capacity to simultaneously decrease PD-1 and FcγRIIB expression in B cells.…”
-
15840
Image 3_Wip1 inhibitor CCT007093 alleviates immune exhaustion of lymphocytes via p65 NF-κB and YY1 in chronic hepatitis B virus infection in mice.tif
Published 2025“…</p>Methods<p>We focused on CCT007093, a Wip1 inhibitor, screened for its distinctive capacity to simultaneously decrease PD-1 and FcγRIIB expression in B cells.…”